| P/E (FY) | 101.8 | Sales (TTM) | ₩4.56T |
| Earnings (TTM) | ₩1.78T | ROE | 19.44% |
| Net Margin | 39.16% | ROIC | 15.71% |
| Debt / Equity | 0.12 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 14.94% |
Samsung Biologics Co., Ltd. and its subsidiaries manufacture, commercialize, distribute and sell biopharmaceutical products in South Korea, Europe, the United States and internationally. Its development services include cell line and process development, analytical development and non-GMP/CGMP manufacturing, while it also provides aseptic filling, lyophilization, finishing, cold chain storage and shipping, regulatory support, quality services and analytical testing, and manufactures drug substance. The company additionally develops and manufactures antibody-drug conjugates and mRNA products.
| Market Cap | $49.96B | Trading Days | 2319 |
| 52W High | 1987000.00 |
| 52W Low | 1228000.00 |
| % Off High | −25.57% |
| YTD | −12.74% | 1Y | −11.42% |
| 3Y | 25.58% | 5Y | 5.59% |
| Since incept. (ann.) | 20.17% |
| Ann. Volatility (1Y) | 40.40% | Ann. Volatility (3Y) | 34.46% |
| Sharpe (1Y) | −0.13 | Sharpe (3Y) | 0.39 |
| Max Drawdown (1Y) | −36.74% | Max Drawdown (3Y) | −36.74% |
| Beta (3Y, vs SPY) | 0.30 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| EW | Edwards Lifesciences Corp | $49.38B | 46.9 |
| 7741.T | HOYA CORPORATION | $49.19B | 31.8 |
| BDX | BECTON DICKINSON & CO | $46.40B | 28.9 |
| ARGX.BR | argenx SE | $54.30B | — |
| IDXX | IDEXX LABORATORIES INC /DE | $44.95B | 43.6 |
| IQV | IQVIA HOLDINGS INC. | $41.32B | 31.6 |
| AGL | agilon health, inc. | $41.04B | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| A | AGILENT TECHNOLOGIES, INC. | $39.63B | 30.7 |
| RVMD | Revolution Medicines, Inc. | $38.46B | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.35B | 123.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. |
| $65.34B |
| 16.8 |
